ResMed Inc
(FRA:RMEA)
€
22.2
0.4 (1.83%)
Market Cap: 33.18 Bil
Enterprise Value: 33.56 Bil
PE Ratio: 32.55
PB Ratio: 6.94
GF Score: 98/100 
Resmed Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 06:50PM GMT
Release Date Price:
€12.46
(-0.02%)
Sean M. Laaman
Morgan Stanley, Research Division - Australian Healthcare Analyst
Pleasure today to be joined by David Pendarvis, SVP, from ResMed. So thank you for your time today, David.
David B. Pendarvis
ResMed Inc. - Chief Administrative Officer, Global General Counsel & Secretary
Thanks for having us, Sean.
Questions & Answers
Sean M. Laaman
Morgan Stanley, Research Division - Australian Healthcare Analyst
Welcome. Maybe start by talking about the company's 2025 strategy and educate us what that means and where you're heading?
David B. Pendarvis
ResMed Inc. - Chief Administrative Officer, Global General Counsel & Secretary
Sure. So ResMed is on a long-term journey, and we've recently solidified in on our 2025 strategy, which is trying to look at least the next 5 years out, but I think the thing I would highlight for ResMed is if you believe ResMed is on the right track and that it's -- in order to believe it's a good investment, you really have
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers